Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841021 · ClinicalTrials.gov registry record · NA
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01841021 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 1 participants.
The verdict
NCT01841021, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentuximab vedotin is better or worse than other treatment patients might be given.
Interventions
- DRUG Brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01841021
The ClinicalTrials.gov registry entry for NCT01841021 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brentuximab vedotin is the first listed.
NCT01841021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01841021 about?
NCT01841021 is a clinical study titled "Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30". The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentu...
What is the current status of trial NCT01841021?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2014-04. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01841021?
The interventions under investigation include: Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT01841021?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.